Review

human gb u87mg cell line (ATCC)

ATCC is a verified supplier

ATCC manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

ATCC human gb u87mg cell line
Human Gb U87mg Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 10459 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+u87mg+gb+cell+line/pmc11124321-172-1-10?v=ATCC
Average 99 stars, based on 10459 article reviews

human gb u87mg cell line - by Bioz Stars, 2026-08

99/100 stars

Images

Image Search Results

Journal: International Journal of Molecular Sciences

Article Title: PML Differentially Regulates Growth and Invasion in Brain Cancer

doi: 10.3390/ijms22126289

Figure Lengend Snippet: Growth evolution of the non-induced U87MG and the PML-OE (U87MG-PML OE) spheroids. ( a ) Representative bright-field images and confocal z-stacks maximum intensity projection scans of the spheroids in the hanging-drop with and without 30 μM DZNeP treatment (growth; growth + DZNeP, respectively). All images depict the spheroids 3 days after their formation and DZNeP treatment. Green represents DsRed-PML IV, red represents DRAQ7 and cyan represents H 2 DC-FDA. Scale bar is set at 100 microns. ( b ) Spatiotemporal growth curves representing the radial expansion of the spheroids in the hanging-drop overtime in control and drug treatment condition with DZNeP at 30 μM concentration.

Article Snippet: The well-established human GB cell line U87MG (ATCC ® HTB-14TM) was used in this work.

Techniques: Control, Concentration Assay

Invasion of the non-induced U87MG and the PML-OE (U87MG-PML OE) spheroids. ( a ) Representative bright-field images and confocal z-stacks maximum intensity projection scans of the spheroids in the invasive ECM-depended condition with and without 30 μΜ DZNeP treatment (Invasion; Invasion + DZNeP, respectively) 72 h after spheroid formation and DZNeP treatment. Green represents DsRed-PML IV, red represents DRAQ7 and cyan represents H 2 DC-FDA. Scale bar is set at 100 microns. ( b ) Spatiotemporal evolution curves representing the radial expansion of the core and the invasive rim of the spheroids within the ECM-depended condition overtime in control and drug treatment condition with DZNeP at 30 μM concentration.

Journal: International Journal of Molecular Sciences

Article Title: PML Differentially Regulates Growth and Invasion in Brain Cancer

doi: 10.3390/ijms22126289

Figure Lengend Snippet: Invasion of the non-induced U87MG and the PML-OE (U87MG-PML OE) spheroids. ( a ) Representative bright-field images and confocal z-stacks maximum intensity projection scans of the spheroids in the invasive ECM-depended condition with and without 30 μΜ DZNeP treatment (Invasion; Invasion + DZNeP, respectively) 72 h after spheroid formation and DZNeP treatment. Green represents DsRed-PML IV, red represents DRAQ7 and cyan represents H 2 DC-FDA. Scale bar is set at 100 microns. ( b ) Spatiotemporal evolution curves representing the radial expansion of the core and the invasive rim of the spheroids within the ECM-depended condition overtime in control and drug treatment condition with DZNeP at 30 μM concentration.

Article Snippet: The well-established human GB cell line U87MG (ATCC ® HTB-14TM) was used in this work.

Techniques: Control, Concentration Assay

In silico simulation curves at the best-fit values of the growth dynamics of the non-invasive non-induced and the PML OE-U87MG spheroids over time. ( a ) non-induced U87MG and ( b ) U87MG-PML OE ( c ) non-induced U87MG spheroids under 30 μM DZNeP treatment and ( d ) U87MG-PML OE spheroids under 30 μM DZNeP treatment. The in vitro estimates are also shown for comparison.

Journal: International Journal of Molecular Sciences

Article Title: PML Differentially Regulates Growth and Invasion in Brain Cancer

doi: 10.3390/ijms22126289

Figure Lengend Snippet: In silico simulation curves at the best-fit values of the growth dynamics of the non-invasive non-induced and the PML OE-U87MG spheroids over time. ( a ) non-induced U87MG and ( b ) U87MG-PML OE ( c ) non-induced U87MG spheroids under 30 μM DZNeP treatment and ( d ) U87MG-PML OE spheroids under 30 μM DZNeP treatment. The in vitro estimates are also shown for comparison.

Article Snippet: The well-established human GB cell line U87MG (ATCC ® HTB-14TM) was used in this work.

Techniques: In Silico, In Vitro, Comparison

Summary of the model fitted parameters under study for the non-invasive condition.

Journal: International Journal of Molecular Sciences

Article Title: PML Differentially Regulates Growth and Invasion in Brain Cancer

doi: 10.3390/ijms22126289

Figure Lengend Snippet: Summary of the model fitted parameters under study for the non-invasive condition.

Article Snippet: The well-established human GB cell line U87MG (ATCC ® HTB-14TM) was used in this work.

Techniques:

In silico simulation curves at the best-fit values of the invasive dynamics of the non-induced and the PML OE- U87MG spheroids over time. ( a ) Non-induced U87MG and ( b ) U87MG-PML OE; ( c ) non-induced U87MG spheroids under 30 μM DZNeP treatment and ( d ) U87MG-PML OE under 30 μM DZNeP treatment. The in vitro estimates are also shown for comparison.

Journal: International Journal of Molecular Sciences

Article Title: PML Differentially Regulates Growth and Invasion in Brain Cancer

doi: 10.3390/ijms22126289

Figure Lengend Snippet: In silico simulation curves at the best-fit values of the invasive dynamics of the non-induced and the PML OE- U87MG spheroids over time. ( a ) Non-induced U87MG and ( b ) U87MG-PML OE; ( c ) non-induced U87MG spheroids under 30 μM DZNeP treatment and ( d ) U87MG-PML OE under 30 μM DZNeP treatment. The in vitro estimates are also shown for comparison.

Article Snippet: The well-established human GB cell line U87MG (ATCC ® HTB-14TM) was used in this work.

Techniques: In Silico, In Vitro, Comparison

Summary of the model fitted parameters under study for the invasive condition, while the non-invasive parameters are kept constant.

Journal: International Journal of Molecular Sciences

Article Title: PML Differentially Regulates Growth and Invasion in Brain Cancer

doi: 10.3390/ijms22126289

Figure Lengend Snippet: Summary of the model fitted parameters under study for the invasive condition, while the non-invasive parameters are kept constant.

Article Snippet: The well-established human GB cell line U87MG (ATCC ® HTB-14TM) was used in this work.

Techniques: Diffusion-based Assay

Fig. 1 H1-Vastatin transfectd tumour cells specifically and suppressed MECs proliferation through paracrine inhibition. a H1 mediated gene transfections targeted only the tumour cells. Enhanced transcription level of Vastatin was only detected in the H1-Vastatin treated U87MG cells. b Proliferation curves of cells treated by H1-Vastatin or H1-EGFP. H1-Vastatin did not affected the proliferation of U87MG cells or MECs in separate culture condition. In the U87MG and MECs co-culure system, H1-Vastatin significantly suppressed the MECs growth on day 7 post treatment (P < 0.05). c Inhibition curves showing effects of different conditioned media (CM) on MECs proliferation. Conditioned medium from H1-Vastatin treated U87MG cells significantly decreased the cell viability of MECs in a dosage dependant way (* P < 0.05 against CM from H1-EGFP treated U87MG cells; # P < 0.05 against CM from H1-Vastatin treated MECs), suggesting Vastatin secreted by tumour cells inhibited neovascularization in paracrine manner

Journal: BMC cancer

Article Title: Enhanced expression of Vastatin inhibits angiogenesis and prolongs survival in murine orthotopic glioblastoma model.

doi: 10.1186/s12885-017-3125-8

Figure Lengend Snippet: Fig. 1 H1-Vastatin transfectd tumour cells specifically and suppressed MECs proliferation through paracrine inhibition. a H1 mediated gene transfections targeted only the tumour cells. Enhanced transcription level of Vastatin was only detected in the H1-Vastatin treated U87MG cells. b Proliferation curves of cells treated by H1-Vastatin or H1-EGFP. H1-Vastatin did not affected the proliferation of U87MG cells or MECs in separate culture condition. In the U87MG and MECs co-culure system, H1-Vastatin significantly suppressed the MECs growth on day 7 post treatment (P < 0.05). c Inhibition curves showing effects of different conditioned media (CM) on MECs proliferation. Conditioned medium from H1-Vastatin treated U87MG cells significantly decreased the cell viability of MECs in a dosage dependant way (* P < 0.05 against CM from H1-EGFP treated U87MG cells; # P < 0.05 against CM from H1-Vastatin treated MECs), suggesting Vastatin secreted by tumour cells inhibited neovascularization in paracrine manner

Article Snippet: Cell lines and Cell culture The murine tumour-derived microvessel endothelial cells (MECs) SVEC4-10EE2 and human GB cell lines U87MG were purchased from American Type Culture Collection (ATCC).

Techniques: Inhibition, Transfection

Fig. 4 Vastatin synergized with temozolomide in GB chemoresistant model. a TMZ resistance of U87-ATR cells. U87-ATR had a much higher half inhibited dosage of TMZ (>800 μM) than U87MG (<50 μM) in the proliferation test (upper). More U87-ATR than U87MG cells survived the treatment of 100 μM TMZ and formed cell colonies (lower). b U87-ATR cells showed enhanced cancer stem cell property by expression of CSC marker CD133. U87-ATR’ were cells amplified from a single cell clone which was picked out from TMZ treated U87-ATR. c Survival curves showing that GB model established using U87-ATR had a much shorter survival time (25 days) than using U87MG cells (50 days, P < 0.05), and did not respond to TMZ treatment (n = 5). d Survival curves of TMZ resistance GB animals treated by H1-Vastatin and/or TMZ (n = 5). H1-Vastatin significantly prolonged the median survival of animals bearing U87-ATR xenografts to 34 days (P < 0.05). The combination of TMZ and H1-Vastatin showed even better therapeutic effects, with median survival extended to 54 days (P < 0.01 against H1-EGFP treated group; P < 0.05 against H1-Vastatin single treatment group). This result suggested Vastatin synergized with TMZ and restored the sensitivity of chemoresistant mice to TMZ treatments

Journal: BMC cancer

Article Title: Enhanced expression of Vastatin inhibits angiogenesis and prolongs survival in murine orthotopic glioblastoma model.

doi: 10.1186/s12885-017-3125-8

Figure Lengend Snippet: Fig. 4 Vastatin synergized with temozolomide in GB chemoresistant model. a TMZ resistance of U87-ATR cells. U87-ATR had a much higher half inhibited dosage of TMZ (>800 μM) than U87MG (<50 μM) in the proliferation test (upper). More U87-ATR than U87MG cells survived the treatment of 100 μM TMZ and formed cell colonies (lower). b U87-ATR cells showed enhanced cancer stem cell property by expression of CSC marker CD133. U87-ATR’ were cells amplified from a single cell clone which was picked out from TMZ treated U87-ATR. c Survival curves showing that GB model established using U87-ATR had a much shorter survival time (25 days) than using U87MG cells (50 days, P < 0.05), and did not respond to TMZ treatment (n = 5). d Survival curves of TMZ resistance GB animals treated by H1-Vastatin and/or TMZ (n = 5). H1-Vastatin significantly prolonged the median survival of animals bearing U87-ATR xenografts to 34 days (P < 0.05). The combination of TMZ and H1-Vastatin showed even better therapeutic effects, with median survival extended to 54 days (P < 0.01 against H1-EGFP treated group; P < 0.05 against H1-Vastatin single treatment group). This result suggested Vastatin synergized with TMZ and restored the sensitivity of chemoresistant mice to TMZ treatments

Techniques: Expressing, Marker, Amplification

Effect of SFN on cell survival. U87MG cells, HUVECs and MSCs were seeded in their standard growth media and were treated with various concentrations of SFN. Cell survival was estimated with the CyQUANT® cell proliferation assay kit. The results obtained for U87MG cells, HUVECs or MSCs cultured with culture medium alone were considered to correspond to 100% survival. Data are expressed as the mean of four wells ± SEM ( n = 3)

Journal: Journal of Experimental & Clinical Cancer Research : CR

Article Title: Human mesenchymal stromal cells as cellular drug-delivery vectors for glioblastoma therapy: a good deal?

doi: 10.1186/s13046-017-0605-2

Figure Lengend Snippet: Effect of SFN on cell survival. U87MG cells, HUVECs and MSCs were seeded in their standard growth media and were treated with various concentrations of SFN. Cell survival was estimated with the CyQUANT® cell proliferation assay kit. The results obtained for U87MG cells, HUVECs or MSCs cultured with culture medium alone were considered to correspond to 100% survival. Data are expressed as the mean of four wells ± SEM ( n = 3)

Article Snippet: The human U87MG GB cell line was obtained from the ATCC (LGC Promochem, Molsheim, France).

Techniques: CyQUANT Assay, Proliferation Assay, Cell Culture

Journal: Journal of Experimental & Clinical Cancer Research : CR

Article Title: Human mesenchymal stromal cells as cellular drug-delivery vectors for glioblastoma therapy: a good deal?

doi: 10.1186/s13046-017-0605-2

Figure Lengend Snippet: SFN release from SFN-primed MSCs and in vitro toxicity of SFN-primed MSCs to U87MG cells and HUVECs. a Profile of in vitro SFN release by SFN-primed MSCs. b and c Viability of U87MG cells and HUVECs following exposure to SFN or SFN-primed MSCs. Two doses of MSCs were tested: 6 × 10 5 and 2 × 10 5 cells, corresponding to the release of about 3.2 μg and 1.1 μg SFN, respectively. The results obtained for U87MG cells and HUVECs cultured with culture medium alone were considered to correspond to 100% survival. Data are expressed as the mean of four wells ± SEM ( n = 2) (* p < 0.05, versus U87MG cells or HUVECs cultured with culture medium alone)

Article Snippet: The human U87MG GB cell line was obtained from the ATCC (LGC Promochem, Molsheim, France).

Techniques: In Vitro, Cell Culture

GB-targeted migration of MSCs after intranasal administration. a Schematic representation of the experimental model. MSCs were administered via the nasal cavity using a pipet tip. After passing the olfactory epithelium (brown), MSCs enter the brain and migrate towards the tumor. b Fluorescence microscopy images of tissue sections after the intranasal injection of MSCs into U87MG tumor-bearing mice. Three days (D15) and seven days (D19) after the intranasal administration of MSCs, the MSCs had migrated and were located within the tumor mass. MSCs were detected by red fluorescent labeling of the Y-chromosome. Nuclei were stained with DAPI. Scale bars = 100 μm. c Quantification of MSCs in the U87MG tumor three and seven days after intranasal administration. Results are expressed as the mean number of Y + MSCs per mm 2 ± SEM (* p < 0.05, versus the number of Y + MSCs observed at day 15)

Journal: Journal of Experimental & Clinical Cancer Research : CR

Article Title: Human mesenchymal stromal cells as cellular drug-delivery vectors for glioblastoma therapy: a good deal?

doi: 10.1186/s13046-017-0605-2

Figure Lengend Snippet: GB-targeted migration of MSCs after intranasal administration. a Schematic representation of the experimental model. MSCs were administered via the nasal cavity using a pipet tip. After passing the olfactory epithelium (brown), MSCs enter the brain and migrate towards the tumor. b Fluorescence microscopy images of tissue sections after the intranasal injection of MSCs into U87MG tumor-bearing mice. Three days (D15) and seven days (D19) after the intranasal administration of MSCs, the MSCs had migrated and were located within the tumor mass. MSCs were detected by red fluorescent labeling of the Y-chromosome. Nuclei were stained with DAPI. Scale bars = 100 μm. c Quantification of MSCs in the U87MG tumor three and seven days after intranasal administration. Results are expressed as the mean number of Y + MSCs per mm 2 ± SEM (* p < 0.05, versus the number of Y + MSCs observed at day 15)

Article Snippet: The human U87MG GB cell line was obtained from the ATCC (LGC Promochem, Molsheim, France).

Techniques: Migration, Fluorescence, Microscopy, Injection, Labeling, Staining

Effect of intranasal administrations of SFN, or of unprimed or SFN-primed MSCs on U87MG growth and angiogenesis. a Representation of the treatment protocol applied to U87MG-bearing mice. b Tumor volume distribution in each group, calculated by MRI on day 17. c Immunofluorescence staining for Ki67 and CD31 in the tumor on day 17 (scale bar = 100 μm). d and e Quantitative results for Ki67 and CD31 immunofluorescence. Results are expressed as the mean number of Ki67 + cells ( d ) or CD31 + vessels ( e ) per mm 2 ± SEM. (ǂ p < 0.05, versus HBSS, SFN and SFN-primed MSCs; * p < 0.05, versus HBSS, SFN and unprimed MSCs)

Journal: Journal of Experimental & Clinical Cancer Research : CR

Article Title: Human mesenchymal stromal cells as cellular drug-delivery vectors for glioblastoma therapy: a good deal?

doi: 10.1186/s13046-017-0605-2

Figure Lengend Snippet: Effect of intranasal administrations of SFN, or of unprimed or SFN-primed MSCs on U87MG growth and angiogenesis. a Representation of the treatment protocol applied to U87MG-bearing mice. b Tumor volume distribution in each group, calculated by MRI on day 17. c Immunofluorescence staining for Ki67 and CD31 in the tumor on day 17 (scale bar = 100 μm). d and e Quantitative results for Ki67 and CD31 immunofluorescence. Results are expressed as the mean number of Ki67 + cells ( d ) or CD31 + vessels ( e ) per mm 2 ± SEM. (ǂ p < 0.05, versus HBSS, SFN and SFN-primed MSCs; * p < 0.05, versus HBSS, SFN and unprimed MSCs)

Article Snippet: The human U87MG GB cell line was obtained from the ATCC (LGC Promochem, Molsheim, France).

Techniques: Immunofluorescence, Staining

Review

Structured Review

Images

Similar Products

Image Search Results